AI for Longevity Summit

Exclusive Invitation-Only Event Uniting Scientists,
AI Experts and Industry Leaders at King’s College London

November 12, 2019, 14:00 - 18:30, King’s College, London UK

Uniting Cross-Sector Experts on AI for Longevity

The inaugural, exclusive and invitation-only AI for Longevity Summit, organized by the Longevity AI Consortium at King’s College London, brings together leading scientists, industry players, and experts to present and discuss the cutting-edge of Artificial Intelligence for ageing research and the practical implementation of longevity technologies and therapeutics. To be held at the Guy's Hospital campus of King's College London on November 12th, it will be the first in a series of conferences, which we expect to become the world-leading forum on AI for Longevity. The next two events in the series will be held in 2020 in London, UK and Geneva, Switzerland.

About the Longevity AI Consortium at King’s College

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the basis of a person’s genes, lifestyle and environment. With the advances in genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality. Leveraging the AI and Longevity expertise at Ageing Research at King’s (ARK) to turn King’s College into an AI for Longevity H&D hub.

International Longevity Policy and Governance Summit

     Major topics of the summit will include:

  • Frontier applications of Artificial Intelligence in ageing research, longevity R&D and the development of biomarkers of health and longevity

  • The paradigm shift from disease treatment and sick care to preventive medicine, and from preventive medicine to precision health, utilizing nearly real-time assessment of biomarkers of ageing to coordinate micro-dose interventions to continually rebalance biomarkers of health and longevity and maintain an optimal state of precision health, and how AI will be necessary for the coordination of biomarker monitoring and interventions due to the sheer volume of data

  • The increasing shift toward actionable biomarkers of ageing, including the identification of biomarkers of health, longevity and aging that have the highest ratios of accuracy and precision vs. actionability, expense and ease-of-implementation, and the benchmarking of biomarkers that can be used in practice today

  • Emerging trends and novel paradigms relating to both the creation and application of life data, including the construction of biomarkers of ageing, longevity and health collected on a massive scale from healthy individuals and used in scientifically-backed, quantifiable, tangible and precise ways to preserve and maintain an optimal state of health

  • The creation of novel forms of biomarkers that are still in the initial R&D phase, including image-recognition and photographic biomarkers of ageing, vocal-recognition based biomarkers of aging, as well as gait, movement and accelerometer-based biomarkers of ageing

  • What biomarkers of health and longevity can be used today to assess individual’s personal state of health and track the effectiveness of behavioural, lifestyle and therapeutic interventions, as well as how and where to gain access to the leading longevity diagnostic and prognostic technologies that are just now reaching the threshold of real-world practical application

  • An overview of how biomarkers of health, longevity and aging can be used at scale by governments to track, measure and test the efficacy of programs and development plans aiming to increase National Healthy Longevity

Awareness of utilising AI technologies within longevity and ageing research is rapidly increasing in both academia and industry. To utilise the latest AI advances and accelerate innovation and technology transfer, Ageing Research at King’s (ARK) has partnered with Biogerontology Research Foundation and our industry partners Insilico Medicine, Deep Knowledge Ventures and Ageing Analytics Agency to establish UK’s first Longevity AI Consortium (LAIC).

Modern deep learning techniques used to develop longevity and ageing predictors offer new possibilities for diverse data types. This will enable a holistic view to identify novel geroprotectors, biomarkers, drug discovery and biotechnology in the longevity, healthcare and pharmaceutical industry. With our partners, ARK and the LAIC are committed to bring together AI expertise across KCL and King’s Health Partners to explore its utility and impact for longevity and ageing research. We will employ a variety of AI-based methods to explore patterns that have significant potential to impact longevity, healthy ageing, age-related diseases and targeted therapeutics from biomedicine to social and economic sciences.

  The major aims of the Longevity AI Consortium include:

  • Identification of novel longevity and healthy ageing biomarkers

  • Development of actionable biomarkers of ageing, health and longevity, with optimal ratios of accuracy vs. implementability

  • R&D on biomarkers designed to test intervention effectiveness

  • Accelerated diagnosis of age-related health decline, with increased accuracy

  • Refining demographic and clinical methods to facilitate recruitment, retention and ongoing reappraisal.

  • Development of personalised health, longevity and treatment practices

  • Promoting effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity and environmental exposure.

577b8e15f4bb5c58573ae849_logo.png
logo_ark.jpg
1200px-King's_College_London_logo.svg.pn